Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.5K
1.5K
Cancer Therapies02:49

Cancer Therapies

2.4K
2.4K
Cancer Therapies02:49

Cancer Therapies

8.6K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
8.6K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.0K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.0K
Cancer02:18

Cancer

51.8K
Cancers arise due to mutations in genes involved in the regulation of cell division, which leads to unrestricted cell proliferation. Modern science and medicine have made great strides in the understanding and treatment of cancer, including eradicating cancer in some patients. However, there is still no cure for cancer. This is largely due to the fact that cancer is a large group of many diseases.
51.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Survey of Secondhand Smoke for 3-Year-Old Children in the Current Era of New Tobacco Products.

Acta paediatrica (Oslo, Norway : 1992)·2025
Same author

Honey suppressed night coughs due to its sweetness not its antibacterial properties.

Acta paediatrica (Oslo, Norway : 1992)·2022
Same author

Multicentre, randomised study found that honey had no pharmacological effect on nocturnal coughs and sleep quality at 1-5 years of age.

Acta paediatrica (Oslo, Norway : 1992)·2022
Same author

LPS modifications and AvrA activity of Salmonella enterica serovar Typhimurium are required to prevent Perforin-2 expression by infected fibroblasts and intestinal epithelial cells.

Microbial pathogenesis·2021
Same author

Impaired B Cell Function in Mice Lacking Perforin-2.

Frontiers in immunology·2020
Same author

An Essential Role for Perforin-2 in Type I IFN Signaling.

Journal of immunology (Baltimore, Md. : 1950)·2020

Related Experiment Video

Updated: May 6, 2026

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
09:56

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

1.5K

CD30: from basic research to cancer therapy.

Hiromi Muta, Eckhard R Podack

    Immunologic Research
    |November 16, 2013
    PubMed
    Summary
    This summary is machine-generated.

    Brentuximab vedotin, an anti-CD30 drug, is FDA-approved for CD30-positive lymphomas. Research reveals CD30

    More Related Videos

    Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis
    07:40

    Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis

    Published on: March 20, 2021

    20.2K
    Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer
    07:55

    Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer

    Published on: January 17, 2025

    1.8K

    Related Experiment Videos

    Last Updated: May 6, 2026

    A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
    09:56

    A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

    Published on: February 21, 2025

    1.5K
    Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis
    07:40

    Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis

    Published on: March 20, 2021

    20.2K
    Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer
    07:55

    Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer

    Published on: January 17, 2025

    1.8K

    Area of Science:

    • Immunology
    • Oncology

    Background:

    • The FDA approved Brentuximab vedotin, an agonistic anti-CD30 drug conjugate, for treating CD30-positive lymphomas.
    • Brentuximab vedotin demonstrates potent clinical activity in Hodgkin's lymphoma and anaplastic large-cell lymphoma, offering a new therapeutic option.
    • The development of this drug originated from basic research, initially unrelated to CD30.

    Purpose of the Study:

    • To describe the hybridoma acquisition process stemming from unrelated basic research.
    • To review the known biological functions of CD30.
    • To elucidate CD30's role in immune cell regulation.

    Main Methods:

    • Review of scientific literature on CD30 biology and Brentuximab vedotin.
    • Description of hybridoma generation techniques.
    • Analysis of data from murine models and patient studies concerning CD30 function.

    Main Results:

    • The hybridoma was obtained through a basic research experiment not initially focused on CD30.
    • CD30's normal biological functions have been investigated in murine models and human patients.
    • Emerging evidence suggests CD30 regulates memory cells, influencing costimulation, trafficking, and apoptosis.

    Conclusions:

    • CD30 plays a critical role in regulating memory cell function.
    • CD30's function is context-dependent, influenced by the microenvironment and cytokine milieu.
    • Understanding CD30's biology is crucial for developing targeted therapies like Brentuximab vedotin.